Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Cited by (1,003)

Items 101–200 of 1,003

1. Glucose Availability Regulates IFN-γ Production and p70S6 Kinase Activation in CD8+ Effector T Cells
   Cham, Candace M, Gajewski, Thomas F · 2005 · The Journal of Immunology
2. Immunosuppressive mechanisms in glioblastoma: Fig. 1.
   Edjah Kweku-Ebura Nduom, Michael Weller, Amy B. Heimberger · 2015 · Neuro-Oncology
3. The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
   Mbongue, Jacques, Nicholas, Dequina, Torrez, Timothy, Kim, Nan-Sun, Firek, Anthony, Langridge, William · 2015 · Vaccines
4. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types
   Hartung, T.J., Brähler, E., Faller, H., Härter, M., Hinz, A., Johansen, C., Keller, M., Koch, U., Schulz, H., Weis, J. et al. · 2017 · European Journal of Cancer
5. Regulatory T-Cell Generation and Kidney Allograft Tolerance Induced by Mesenchymal Stem Cells Associated With Indoleamine 2,3-Dioxygenase Expression
   Wei Ge, Jifu Jiang, Jacqueline Arp, Weihua Liu, Bertha M Garcia, Hao Wang · 2010 · Transplantation
6. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism
   Osamu Takikawa · 2005 · Biochemical and Biophysical Research Communications
7. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
   Yanqi Ye, Jinqiang Wang, Quanyin Hu, Gabrielle M. Hochu, Hongliang Xin, Chao Wang, Zhen Gu · 2016 · ACS Nano
8. Twelve immunotherapy drugs that could cure cancers
   Martin A. Cheever · 2008 · Immunological Reviews
9. T Cell Dysfunction in Cancer Immunity and Immunotherapy
   Anliang Xia, Yan Zhang, Xu Jiang, Tailang Yin, Xiaojie Lu · 2019 · Frontiers in Immunology
10. Targeting the indoleamine 2,3-dioxygenase pathway in cancer
    Yong Wha Moon, Joud Hajjar, Patrick Hwu, Aung Naing · 2015 · Journal for ImmunoTherapy of Cancer
11. Cytokines as a key component of cancer-related inflammation
    Giovanni Germano, Paola Allavena, Alberto Mantovani · 2008 · Cytokine
12. Oncolytic viruses in cancer therapy
    Markus J. V. Vähä-Koskela, Jari Heikkilä, Ari Hinkkanen · 2007 · Cancer Letters
13. Trial watch: IDO inhibitors in cancer therapy
    Erika Vacchelli, Fernando Aranda, Alexander M.M. Eggermont, Catherine Sautès‐Fridman, Éric Tartour, Eugene Paul Kennedy, Michael Platten, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2014 · OncoImmunology
14. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
    Lijie Zhai, Stefani Spranger, David C. Binder, Galina Gritsina, Kristen L. Lauing, Francis Joseph Giles, Derek Alan Wainwright · 2015 · Clinical Cancer Research
15. Characterization of the Kynurenine Pathway in Human Neurons
    Gilles J. Guillemin, Karen M. Cullen, Chai K. Lim, George A. Smythe, Brett Garner, Vimal Kapoor, Osamu Takikawa, Bruce James Brew · 2007 · Journal of Neuroscience
16. Immune escape as a fundamental trait of cancer: focus on IDO
    George C. Prendergast · 2008 · Oncogene
17. Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy
    Keman Cheng, Yanping Ding, Ying Zhao, Shefang Ye, Xiao Zhao, Yinlong Zhang, Tianjiao Ji, Huanhuan Wu, Bin Wang, Gregory Jon Anderson et al. · 2018 · Nano Letters
18. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
    Ulrike M. Litzenburger, Christiane A. Opitz, Felix Sahm, Katharina J. Rauschenbach, Saskia Trump, Marcus Winter, Martina Ott, Katharina Ochs, Christian Lutz, Xiangdong Liu et al. · 2014 · Oncotarget
19. IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
    Courtney Smith, Mee Young Chang, Katherine H. Parker, Daniel W. Beury, James B. DuHadaway, Hollie E. Flick, Janette Boulden, Erika Sutanto‐Ward, Alejandro Peralta Soler, Lisa D. Laury‐Kleintop et al. · 2012 · Cancer Discovery
20. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer
    Lena Cords, Stefanie Engler, Martina Haberecker, Jan H. Rüschoff, Holger Moch, Natalie de Souza, Bernd Bodenmiller · 2024 · Cancer Cell
21. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
    Soranobu Ninomiya, Neeharika Narala, Leslie E. Huye, Shigeki Yagyu, Barbara Savoldo, Gianpietro Dotti, Helen Elisabeth Heslop, Malcolm K. Brenner, Cliona M. Rooney, Carlos A. Ramos · 2015 · Blood
22. Emerging targets in cancer immunotherapy
    Samantha Burugu, Amanda R. Dancsok, Torsten O. Nielsen · 2017 · Seminars in Cancer Biology
23. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies
    Beatty, Gregory L., O'Dwyer, Peter J., Clark, Jason, Shi, Jack G., Bowman, Kevin J., Scherle, Peggy A., Newton, Robert C., Schaub, Richard, Maleski, Janet, Leopold, Lance et al. · 2017 · Clinical Cancer Research
24. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer
    Chien‐Ying Liu, Yumin Wang, Chih-Liang Wang, Po‐Hao Feng, How‐Wen Ko, Yun‐Hen Liu, Yi‐Cheng Wu, Yen Chu, Fu‐Tsai Chung, Chih-Hsi Scott Kuo et al. · 2009 · Journal of Cancer Research and Clinical Oncology
25. Inflammatory cell infiltration of tumors: Jekyll or Hyde
    James E. Talmadge, Moses K. Donkor, Eric M. Scholar · 2007 · Cancer and Metastasis Reviews
26. Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
    Riera-Domingo, Carla, Audigé, Annette, Granja, Sara, Cheng, Wan-Chen, Ho, Ping-Chih, Baltazar, Fátima, Stockmann, Christian, Mazzone, Massimiliano · 2020 · Physiological Reviews
27. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Yu Fujiwara, Shumei Kato, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock · 2022 · Cancer Treatment Reviews
28. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
    Garg, Abhishek D., Dudek, Aleksandra M., Ferreira, Gabriela B., Verfaillie, Tom, Vandenabeele, Peter, Krysko, Dmitri V., Mathieu, Chantal, Agostinis, Patrizia · 2013 · Autophagy
29. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
    Stefan Löb, Alfred Königsrainer, Derek Zieker, Björn L.D.M. Brücher, Hans‐Georg Rammensee, Gerhard Opelz, Peter Terness · 2008 · Cancer Immunology Immunotherapy
30. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
    Eddy W. Yue, Richard B. Sparks, Padmaja K Polam, Dilip Modi, Brent D. Douty, Brian R. Wayland, Brian M. Glass, Amy G. Takvorian, Joseph Glenn, Wenyu Zhu et al. · 2017 · ACS Medicinal Chemistry Letters
31. Stromal Cells in the Tumor Microenvironment
    Alice E. Denton, Edward W. Roberts, Douglas T. Fearon · 2018 · Advances in experimental medicine and biology
32. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy
    Hathaichanok Phuengkham, Long Fang Ren, Il Woo Shin, Yong Taik Lim · 2019 · Advanced Materials
33. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
    Nicholas A. Ullman, Paul R. Burchard, Richard Francis Dunne, David C. Linehan · 2022 · Journal of Clinical Oncology
34. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
    Ciriana Orabona, Ursula Grohmann, Maria Laura Belladonna, Francesca Fallarino, Carmine Vacca, Roberta Bianchi, Silvia Bozza, Claudia Volpi, Benoı̂t L. Salomon, Maria Cristina Fioretti et al. · 2004 · Nature Immunology
35. The therapeutic potential of targeting tryptophan catabolism in cancer
    Opitz, Christiane A., Somarribas Patterson, Luis F., Mohapatra, Soumya R., Dewi, Dyah L., Sadik, Ahmed, Platten, Michael, Trump, Saskia · 2020 · British Journal of Cancer
36. Effector and regulatory events during natural killer–dendritic cell interactions
    Lorenzo Moretta, Guido Ferlazzo, Cristina Bottino, Massimo Vitale, Daniela Pende, Maria Cristina Mingari, Alessandro Moretta · 2006 · Immunological Reviews
37. Lipoxygenase metabolism: roles in tumor progression and survival
    Graham P. Pidgeon, Joanne Lysaght, Sriram Krishnamoorthy, John Vincent Reynolds, Kenneth John O'Byrne, Daotai Nie, Kenneth V. Honn · 2007 · Cancer and Metastasis Reviews
38. The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
    Fearon, Douglas T. · 2014 · Cancer Immunology Research
39. Tryptophan Metabolism as a Pharmacological Target
    Morgane Modoux, Nathalie Rolhion, Sridhar Mani, Harry Sokol · 2020 · Trends in Pharmacological Sciences
40. Nanomaterials for cancer immunotherapy
    Wantong Song, Sara Musetti, Leaf Huang · 2017 · Biomaterials
41. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
    Kyung Hae Jung, Patricia Mucci LoRusso, Howard A. Burris, Michael S. Gordon, Yung‐Jue Bang, Matthew David Hellmann, Andrès M.R. Cervantes, María Ochoa de Olza, Aurélien Marabelle, Frank Stephen Hodi et al. · 2019 · Clinical Cancer Research
42. Immune control by amino acid catabolism during tumorigenesis and therapy
    Henrique de Paula Lemos, Lei Huang, George C. Prendergast, Andrew L. Mellor · 2019 · Nature reviews. Cancer
43. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
    Annie A. Wu, Virginia E. Drake, Huai-Shiuan Huang, ShihChi Chiu, Lei Zheng · 2015 · OncoImmunology
44. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
    George C. Prendergast, William P. Malachowski, Arpita Mondal, Peggy Scherle, Alexander J. Muller · 2017 · International review of cytology
45. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
    Liève Brochez, Inès Chevolet, Vibeke Krüse · 2017 · European Journal of Cancer
46. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization
    Su-Mei Chen, Haitao Zhu, Y. Jounaidi · 2024 · Signal Transduction and Targeted Therapy
47. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
    Alexander J. Muller, Mark G Manfredi, Yousef Zakharia, George C. Prendergast · 2018 · Seminars in Immunopathology
48. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
    Alexander J. Muller, Peggy Scherle · 2006 · Nature reviews. Cancer
49. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
    Yuzo Suzuki, Takafumi Suda, Kazuki Furuhashi, Masako Suzuki, Michio Fujie, Dai Hahimoto, Yutaro Nakamura, Naoki Inui, Hirotoshi Nakamura, Kingo Chida · 2009 · Lung Cancer
50. Synthetic Fe/Cu Complexes: Toward Understanding Heme-Copper Oxidase Structure and Function
    Suzanne M. Adam, Gayan B. Wijeratne, Patrick J. Rogler, Daniel E. Díaz, David A. Quist, Jeffrey J. Liu, Kenneth D. Karlin · 2018 · Chemical Reviews
51. Tryptophan and indole metabolism in immune regulation
    Alessandra Fiore, Peter J. Murray · 2021 · Current Opinion in Immunology
52. Immune Suppression in the Tumor Microenvironment
    Thomas Frank Gajewski, Yuru Meng, Helena Harlin · 2006 · Journal of Immunotherapy
53. BiTEs: bispecific antibody constructs with unique anti-tumor activity
    Wolf, Evelyn, Hofmeister, Robert, Kufer, Peter, Schlereth, Bernd, Baeuerle, Patrick A. · 2005 · Drug Discovery Today
54. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
    Antonio Curti, Sara Trabanelli, Valentina Salvestrini, Michele Baccarani, Roberto Massimo Lemoli · 2008 · Blood
55. A Convergence-Based Framework for Cancer Drug Resistance
    Konieczkowski, David J., Johannessen, Cory M., Garraway, Levi A. · 2018 · Cancer Cell
56. IDO and tolerance to tumors
    David H. Munn, Andrew L. Mellor · 2003 · Trends in Molecular Medicine
57. STAT1 and STAT3 in tumorigenesis
    Lidia Avalle, Sara Pensa, Gabriella Regis, Francesco Novelli, Valeria Poli · 2012 · JAK-STAT
58. Targeting T cell metabolism for therapy
    David O’Sullivan, Erika L. Pearce · 2015 · Trends in Immunology
59. The tumor‐draining lymph node as an immune‐privileged site
    David H. Munn, Andrew L. Mellor · 2006 · Immunological Reviews
60. Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy
    Gajewski, Thomas F., Louahed, Jamila, Brichard, Vincent G. · 2010 · The Cancer Journal
61. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
    Jin Won Kim, Kyung Han Nam, Sang-Hoon Ahn, Do Joong Park, Hyung‐Ho Kim, Se Hyun Kim, Hyun Kyung Chang, Jeong‐Ok Lee, Yu Jung Kim, Hye Seung Lee et al. · 2014 · Gastric Cancer
62. Clinical cancer immunotherapy: Current progress and prospects
    Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen, Di Zhu · 2022 · Frontiers in Immunology
63. Natural and Induced T Regulatory Cells in Cancer
    Dennis O. Adeegbe, Hiroyoshi Nishikawa · 2013 · Frontiers in Immunology
64. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
    Kazuhiko Ino, N Yoshida, Hiroaki Kajiyama, Kiyosumi Shibata, Eiko Yamamoto, Kumiko Kidokoro, Noriko K. Takahashi, Mikio Terauchi, A. Nawa, Seiji Nomura et al. · 2006 · British Journal of Cancer
65. Whole tumor antigen vaccines
    Cheryl Lai-Lai Chiang, Fabián Benencia, George Coukos · 2010 · Seminars in Immunology
66. The immune system and inflammation in breast cancer
    Xinguo Jiang, David J. Shapiro · 2013 · Molecular and Cellular Endocrinology
67. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
    Holly K. Koblish, Michael Hansbury, Kevin Bowman, Gengjie Yang, Claire L. Neilan, Patrick J. Haley, Timothy C. Burn, Paul Waeltz, Richard B. Sparks, Eddy W. Yue et al. · 2010 · Molecular Cancer Therapeutics
68. Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
    Kazuhiko Ino, Eiko Yamamoto, Kiyosumi Shibata, Hiroaki Kajiyama, Norio Yoshida, Mikio Terauchi, Akihiro Nawa, Tetsuro Nagasaka, Osamu Takikawa, Fumitaka Kikkawa · 2008 · Clinical Cancer Research
69. Glutamine Metabolism in Cancer
    Ting Li, Anne Le · 2018 · Advances in experimental medicine and biology
70. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen
    Christophe Lurquin, Bernard Lethé, Etienne De Plaen, Véronique Corbière, Ivan Théate, Nicolas van Baren, Pierre G. Coulie, Thierry Boon · 2005 · The Journal of Experimental Medicine
71. Immunomodulatory Properties of Mesenchymal Stem Cells: Cytokines and Factors
    Ehsan Soleymaninejadian, Krishna Pramanik, Esmaeil Samadian · 2011 · American Journal of Reproductive Immunology
72. Improving T Cell Therapy for Cancer
    Ann Marie Leen, Cliona M. Rooney, Aaron Edward Foster · 2006 · Annual Review of Immunology
73. Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
    Gabriella Regis, Sara Pensa, Daniela Boselli, Francesco Novelli, Valeria Poli · 2008 · Seminars in Cell and Developmental Biology
74. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition
    Michael S. von Bergwelt‐Baildon, Alexey Popov, Tomo Šarić, Jens Markus Chemnitz, Sabine Claßen, Marc S. Stoffel, Francesca Fiore, Udo Roth, Marc Beyer, Svenja Debey et al. · 2006 · Blood
75. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
    Gregory K. Pennock, Laura Q.M. Chow · 2015 · The Oncologist
76. Role of indoleamine 2,3-dioxygenase in health and disease
    Amanda W. S. Yeung, Andrew C. Terentis, Nicholas J. C. King, Shane Ross Thomas · 2015 · Clinical Science
77. Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
    Nicolas van Baren, Benoit J. Van den Eynde · 2015 · Frontiers in Immunology
78. Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
    Thomas Frank Gajewski · 2007 · Clinical Cancer Research
79. Cancer Metabolism: Current Understanding and Therapies
    Jessica L. Counihan, Elizabeth A. Grossman, Daniel K. Nomura · 2018 · Chemical Reviews
80. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment
    Diego Omar Croci, Mariano F. Zacarías Fluck, María José Rico, Pablo Matar, Gabriel A. Rabinovich, Olga Graciela Scharovsky · 2007 · Cancer Immunology Immunotherapy
81. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
    Jiaqiao Fan, Mengfei Wang, Hailong Chen, Dong Shang, Jugal Kishore Das, Jianxun Jim Song · 2020 · Molecular Cancer
82. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
    Lijie Zhai, April Bell, Erik Ladomersky, Kristen L. Lauing, Lakshmi Reddy Bollu, Jeffrey Alan Sosman, Bin Zhang, Jennifer D. Wu, Stephen D. Miller, Joshua J. Meeks et al. · 2020 · Frontiers in Immunology
83. Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer
    Jinpu Yu, Yue Wang, Yan Fang, Peng Zhang, Hui Li, Hua Zhao, Cihui Yan, Yan Liang Fan, Xiubao Ren · 2014 · The Journal of Immunology
84. The Physiological Action of Picolinic Acid in the Human Brain
    Ross Grant, Sarah E. Coggan, George A. Smythe · 2009 · International Journal of Tryptophan Research
85. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?
    Celalettin Üstün, Jeffrey S. Miller, David H. Munn, Daniel Jordan Weisdorf, Bruce R. Blazar · 2011 · Blood
86. Metabolomic adaptations and correlates of survival to immune checkpoint blockade
    Li, Haoxin, Bullock, Kevin, Gurjao, Carino, Braun, David, Shukla, Sachet A., Bossé, Dominick, Lalani, Aly-Khan A., Gopal, Shuba, Jin, Chelsea, Horak, Christine et al. · 2019 · Nature Communications
87. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
    Tomoko Inaba, Kazuhiko Ino, Hiroaki Kajiyama, Eiko Yamamoto, Kiyosumi Shibata, Akihiro Nawa, Tetsuro Nagasaka, Hidetoshi Akimoto, Osamu Takikawa, Fumitaka Kikkawa · 2009 · Gynecologic Oncology
88. Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function
    Merav E. Shaul, Zvi Gregorio Fridlender · 2018 · FEBS Journal
89. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
    Micah T. Nelp, Patrick A. Kates, John T. Hunt, John A. Newitt, Aaron Balog, Derrick Maley, Xiao Bing Zhu, Lynn M. Abell, Alban J. Allentoff, R. M. Borzilleri et al. · 2018 · Proceedings of the National Academy of Sciences
90. A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments
    Akio Ohta, Akiko Ohta, Manasa Mahathi Madasu, Radhika Kini, Meenakshi Subramanian, Nipun Goel, Michail V. Sitkovsky · 2009 · The Journal of Immunology
91. Metabolic Control of Dendritic Cell Functions: Digesting Information
    Stefanie K. Wculek, Sofía C. Khouili, Elena Priego, Ignacio Heras‐Murillo, David Sancho · 2019 · Frontiers in Immunology
92. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis
    Kumar S. Bishnupuri, David M. Alvarado, Alexander N. Khouri, Mark Shabsovich, Baosheng Chen, Brian Keith Dieckgraefe, Matthew A. Ciorba · 2019 · Cancer Research
93. Metabolite interactions between host and microbiota during health and disease: Which feeds the other?
    Yan Zhang, Rui Chen, DuoDuo Zhang, Shuang Qi, Yan Liu · 2023 · Biomedicine & Pharmacotherapy
94. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells
    Xianfeng Wang, Hongsheng Wang, Hao Wang, Fan Zhang, Ke-Fang Wang, Qiang Guo, Ge Zhang, Shaohui Cai, Jun Du · 2014 · Cellular Immunology
95. Current Perspectives in Cancer Immunotherapy
    Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, Massimo Libra, Apostolos Zaravinos · 2019 · Cancers
96. IDO Expression in Cancer: Different Compartment, Different Functionality?
    Annabel Meireson, Michaël Devos, Liève Brochez · 2020 · Frontiers in Immunology
97. Immune system: a double-edged sword in cancer
    Lakshmi Narendra, Bodduluru, Eshvendar Reddy, Kasala, Shantikumar, Saladi, Ramakrishna, Sistla · 2013 · Inflammation Research
98. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Ute F. Röhrig, Somi Reddy Majjigapu, Pierre Vogel, Vincent Zoete, Olivier Alain Michielin · 2015 · Journal of Medicinal Chemistry
99. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
    Darryl A. Oble, Robert P. Loewe, Ping Yu, Martín C. Mihm · 2009 · PubMed Central
100. Biologically active quinoline and quinazoline alkaloids part II
     Xiaofei Shang, Susan Lynne Morris-Natschke, Guan‐Zhou Yang, Ying‐Qian Liu, Xiao Guo, Xiaoshan Xu, Masuo Goto, Juncai Li, Jiyu Zhang, Kuo‐Hsiung Lee · 2018 · Medicinal Research Reviews